Repatha Cost in Florida 2026: Prices, Insurance, Medicaid, and Compounded Alternatives

What Is Evolocumab and Why Does Cost Matter So Much?

Evolocumab (brand name Repatha) is a fully human monoclonal antibody that blocks PCSK9, a protein that degrades LDL receptors on liver cells. By preserving those receptors, the drug lowers LDL cholesterol by roughly 59% compared with placebo, as shown in the landmark FOURIER trial published in the New England Journal of Medicine in 2017 [1]. FOURIER enrolled 27,564 patients with established atherosclerotic cardiovascular disease (ASCVD) and demonstrated a 15% reduction in major adverse cardiovascular events over a median follow-up of 2.2 years [1].

Cost is the central barrier. At approximately $580 per month, a year of therapy runs close to $7,000 out of pocket for uninsured Floridians. Florida has one of the highest uninsured rates in the United States, with the Kaiser Family Foundation estimating that roughly 2.8 million non-elderly Floridians lacked insurance coverage as of 2023 [2]. That gap makes drug-access navigation a practical clinical concern, not a theoretical one.

The FDA approved evolocumab in August 2015 for adults with primary hyperlipidemia, HeFH, HoFH, and established ASCVD who need additional LDL lowering on top of maximally tolerated statin therapy [3]. The approval label specifies subcutaneous administration at 140 mg every two weeks or 420 mg once monthly for most indications [3].

A 2023 systematic review in JAMA Cardiology covering 27 PCSK9 inhibitor trials confirmed that every 1 mmol/L (about 38.7 mg/dL) reduction in LDL-C translates to an approximate 22% reduction in major vascular events, a relationship that holds across statin and non-statin therapies alike [4]. That efficacy data strengthens the clinical case, but cost remains the practical hurdle for most Florida patients.

Brand-Name Repatha Cash Price in Florida: What You Will Actually Pay

Without insurance or a discount program, Repatha's manufacturer wholesale acquisition cost (WAC) sits near $580 per month in 2026. Cash prices at major Florida retail pharmacy chains, including CVS, Walgreens, and Publix, track closely to that figure. GoodRx and similar discount aggregators typically show cash prices between $540 and $590 for a two-pen supply (140 mg/mL auto-injectors) at Florida zip codes as of mid-2025 [5].

Prices vary by dosing schedule. The once-monthly 420 mg dose (three 140 mg injections administered in sequence) carries the same monthly cost as the biweekly regimen because Amgen prices both schedules at equivalent monthly units. Mail-order pharmacies do not reliably reduce cost on brand evolocumab the way they do for generic drugs.

Specialty pharmacy routing is common. Most insurance plans, including those operating in Florida, require Repatha to be dispensed through a contracted specialty pharmacy such as Accredo, CVS Specialty, or Walgreens Specialty rather than a standard retail counter. That adds an administrative step but does not change the list price.

The American College of Cardiology's 2022 expert consensus decision pathway on nonstatin therapy recommends PCSK9 inhibitors as a first-line nonstatin option for patients with ASCVD whose LDL-C remains at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe [6]. That guideline helps clinicians support prior authorization requests, which nearly all Florida payers require before approving payment.

Florida Medicaid Coverage of Repatha: A Narrow Window

Florida Medicaid does not cover Repatha broadly. Coverage is limited to an extremely narrow pathway related to Type 2 diabetes management and does not extend to the typical ASCVD or familial hypercholesterolemia indications for which most patients are prescribed the drug [7].

That restriction is significant. Florida's Medicaid program, operated through managed care plans under the Statewide Medicaid Managed Care (SMMC) system, gives individual plans latitude to set formularies. Most Florida Medicaid managed care plans, including Molina, Simply, and Sunshine Health, exclude PCSK9 inhibitors entirely from their commercial Medicaid formularies as of 2025 [7].

Patients with both HoFH and Medicaid enrollment face the most difficult access problem. HoFH is a severe genetic disorder affecting roughly 1 in 300,000 people and carries LDL levels that can exceed 500 mg/dL [8]. Even in those cases, Florida Medicaid's formulary restrictions make approval unlikely without a successful appeal citing medical necessity.

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol states directly: "For patients with HeFH and LDL-C greater than or equal to 100 mg/dL on maximally tolerated statin and ezetimibe, addition of a PCSK9 inhibitor is recommended (Class I, Level B-R)" [9]. Florida Medicaid's non-coverage does not align with that recommendation, and clinicians can cite Guideline Class I language in formal appeals.

For patients who fail a Medicaid appeal, compounded evolocumab (discussed in the next section) and the Amgen patient assistance program represent the two primary financial alternatives [10].

Is Compounded Evolocumab Legal in Florida?

Compounded evolocumab is legal in Florida when prepared by a state-licensed 503A compounding pharmacy operating under oversight of the Florida Department of Health and the Florida Board of Pharmacy. The keyword is "503A," which refers to the section of the Federal Food, Drug, and Cosmetic Act governing traditional patient-specific compounding pharmacies as distinct from 503B outsourcing facilities [11].

The legality hinges on three conditions. First, a valid patient-specific prescription from a licensed prescriber must accompany the order. Second, the compounding pharmacy must not produce the formulation in commercially available quantities that would constitute manufacturing. Third, the pharmacy must comply with USP Chapter 797 sterility standards, which apply to all injectable compounded preparations [12].

Florida's Board of Pharmacy enforces these requirements through inspection cycles. Pharmacies found to be compounding beyond patient-specific need or without adequate sterility protocols face suspension or revocation of their license [13]. Patients should verify that any pharmacy they use holds an active Florida 503A license before ordering.

Cost at licensed 503A compounders varies considerably. Some compounding pharmacies offer evolocumab formulations in the $0 to $150 per month range, though pricing depends on the formulation, concentration, and specific pharmacy's sourcing costs. Patients should obtain written documentation of the sterility testing protocol, the active pharmaceutical ingredient source, and the beyond-use date before accepting any compounded injectable.

The FDA has not approved any compounded version of evolocumab, and compounded biologics carry different stability and immunogenicity profiles than the commercially manufactured product [14]. Prescribers should document patient counseling about that distinction in the medical record.

A 2021 statement from the Endocrine Society noted that compounded versions of hormone therapies and other complex molecules warrant case-by-case clinical judgment, acknowledging that access barriers sometimes make compounding the only realistic path for low-income patients [15]. That reasoning applies directly to evolocumab for Florida patients locked out of Medicaid and unable to afford the brand list price.

How the Amgen Repatha Savings Card Works in Florida

The Amgen Repatha Copay Card is the single most effective cost-reduction tool for commercially insured Florida patients. Eligible patients pay $0 per month for up to 24 months, with Amgen covering the remaining copay up to a defined annual cap [16].

Eligibility requirements are strict. The card is available only to patients with commercial insurance, meaning employer-sponsored plans, ACA marketplace plans, and private individual plans. It does not apply to patients covered by Medicare, Medicaid, or any other federally funded program, because federal anti-kickback statutes prohibit manufacturer copay assistance for those beneficiaries [16].

Enrollment takes roughly five minutes at Amgen's Repatha support website. The prescriber's NPI number, the patient's insurance information, and a valid Florida address are required. Once enrolled, the card functions like a secondary insurance payer at participating pharmacies.

Florida ACA marketplace enrollees in Silver or Gold tier plans frequently carry Repatha in Tier 4 or Tier 5 specialty drug categories, which typically means a 25% to 50% coinsurance before the out-of-pocket maximum. The Amgen copay card covers that coinsurance for eligible patients, reducing the effective monthly cost to zero during the card's coverage period [16].

After 24 months, or if the copay card benefit is exhausted, patients may apply for the Amgen Safety Net Foundation program, which provides free drug to patients with household income at or below 600% of the Federal Poverty Level who are uninsured or underinsured [17]. In 2026 to 600% FPL for a family of four is approximately $195,000, a threshold that captures a substantial portion of middle-income Florida households.

Medicare Part D Coverage of Repatha in Florida

Medicare Part D plans in Florida treat evolocumab as a specialty tier drug, which means patients typically face a 25% to 33% coinsurance during the coverage gap and initial coverage phases. Under the Inflation Reduction Act provisions taking full effect in 2025, Medicare Part D out-of-pocket costs for all covered drugs are capped at $2,000 per calendar year [18].

That cap matters significantly for Repatha patients. A Florida Medicare beneficiary who previously reached the catastrophic coverage threshold spending well over $7,000 annually now faces a $2,000 hard ceiling on total Part D spending across all drugs. For patients on multiple specialty medications, the cap creates meaningful financial relief.

The specific Part D formulary placement varies by plan. Florida's Medicare Advantage market includes plans from UnitedHealthcare, Humana, Aetna, and several BCBS affiliates. Each negotiates separate rebate agreements with Amgen, which drives plan-to-plan variation in Repatha's cost sharing. The Medicare Plan Finder tool at cms.gov allows direct comparison of Repatha cost sharing across all Part D-creditable plans serving a Florida zip code [18].

Low-income subsidy (LIS) beneficiaries, sometimes called "Extra Help" recipients, pay nominal copays of $4.50 to $11.20 per prescription regardless of tier in 2026 [19]. Florida has approximately 500,000 Part D LIS recipients, and those individuals who qualify clinically for Repatha face no meaningful cost barrier under their plans [19].

Prior Authorization in Florida: What Triggers Approval

Virtually every Florida commercial plan, Medicare Advantage plan, and the narrow Florida Medicaid pathway that covers Repatha requires a prior authorization (PA) before dispensing. PA criteria typically align with ACC/AHA guidelines but add plan-specific thresholds [9].

Most Florida plans require all of the following for PA approval. The patient must have documented ASCVD (prior MI, stroke, or symptomatic peripheral artery disease) or HeFH confirmed by genetic testing or clinical criteria. The patient must be on maximally tolerated statin therapy, documented in the chart. LDL-C must remain at or above 70 mg/dL for ASCVD patients or 100 mg/dL for HeFH patients despite statin plus ezetimibe. The prescriber must be a cardiologist or endocrinologist, or a primary care physician with specialist co-signature, depending on the plan [9].

Documentation of a statin intolerance trial is sometimes required. Plans may ask for records of at least two separate statins trialed at different doses, with documented adverse effects or contraindications for each, before approving PCSK9 inhibitor therapy without a statin [20].

Appeals succeed most often when the PA submission includes the specific LDL value, the statin trial history, and a direct quotation from ACC/AHA guideline language supporting Class I or Class IIa recommendation for the patient's clinical scenario. The 2022 ACC expert consensus document states: "For very high-risk ASCVD patients not at goal on maximally tolerated statin plus ezetimibe, addition of a PCSK9 inhibitor is reasonable (Class IIa)" [6].

Telehealth Prescribing of Repatha in Florida

Telehealth prescribing of Repatha is legal in Florida for patients with an established clinical relationship. Florida's telehealth statute, codified at Florida Statutes Section 456.47, permits prescription of controlled and non-controlled drugs via synchronous audio-video encounters once a prescriber has reviewed relevant patient history and established a diagnosis [21].

Evolocumab is not a controlled substance, which simplifies the telehealth prescribing pathway. A cardiologist or lipidologist operating a telehealth practice in Florida can prescribe Repatha after reviewing lab values (LDL panel, basic metabolic panel, liver function tests), medication history, and cardiovascular risk documentation without requiring an in-person visit.

HealthRX clinicians conduct telehealth encounters for lipid management that include LDL-C review, statin optimization, and, where indicated, evolocumab initiation. Labs can be ordered to any Florida draw site, and the PA process is handled by the clinical team in coordination with the patient's specialty pharmacy.

Florida's telehealth law does not require a prior in-person visit for new patients seeing a telehealth-only practice, though individual payers may impose their own requirements for PA approvals on telehealth-initiated prescriptions [21]. Patients should confirm with their insurer whether telehealth-initiated specialty prescriptions require any additional documentation.

Comparing All Cost Paths for Florida Patients in 2026

The realistic monthly cost of evolocumab in Florida depends almost entirely on insurance status and income. Here is a direct summary.

Uninsured patients paying cash face the full ~$580 list price or slightly less through GoodRx-type discount programs. Their best options are the Amgen Safety Net Foundation (free drug for income at or below 600% FPL) or a licensed 503A compounding pharmacy [17].

Commercially insured patients with the Amgen Copay Card pay $0 per month for up to 24 months. After that, they may qualify for the Safety Net Foundation if income permits, or they absorb the plan's copay structure [16].

Medicare Part D beneficiaries face a maximum $2,000 annual out-of-pocket cap in 2026. LIS recipients pay $4.50 to $11.20 per fill [19]. Non-LIS beneficiaries may still face several hundred dollars per month until the cap is reached, making the first few months of the year expensive.

Florida Medicaid enrollees for non-diabetes indications have no formulary path and must rely on appeal, the Safety Net Foundation, or compounding pharmacy access [7].

HeFH patients of any insurance status should also ask their prescriber about lomitapide (Juxtapid), mipomersen (Kynamro), or inclisiran (Leqvio) as alternative or adjunctive agents; inclisiran requires only two injections per year and has its own distinct PA and cost structure [22].

A 2022 analysis in Circulation estimated that PCSK9 inhibitors become cost-effective at a threshold of $100,000 per quality-adjusted life year when the drug price falls below approximately $450 per month, which is close to the current negotiated price many large commercial plans achieve through rebates [23]. That figure supports the argument that plans denying PA on cost grounds, rather than clinical grounds, are operating outside standard cost-effectiveness benchmarks.

What Florida Patients Should Bring to Their First Appointment

Preparation shortens the PA process substantially. Patients scheduling a telehealth or in-person appointment to initiate Repatha should bring or have available: a fasting lipid panel drawn within the past 90 days, documentation of current and past statin prescriptions with dates and doses, any records of statin-related side effects, a list of current medications, and their insurance card including the pharmacy benefit manager (PBM) contact number.

Genetic testing results for familial hypercholesterolemia, if available, strengthen PA requests significantly. Cascade screening for FH is recommended by the National Lipid Association and covered under many Florida commercial plans as a preventive service [24]. A confirmed pathogenic variant in LDLR, APOB, or PCSK9 genes essentially guarantees PA approval on most plan criteria.

If genetic testing has not been done, the Dutch Lipid Clinic Network (DLCN) score provides a validated clinical criteria tool for probable or definite HeFH diagnosis that most PA reviewers accept as equivalent to genetic confirmation [25].

A score of 6 to 8 on the DLCN criteria indicates probable HeFH, and a score above 8 indicates definite HeFH. Both categories satisfy most Florida commercial payer PA criteria without requiring genetic documentation [25].